US › Healthcare

Pharvaris BV (PHVS)

US · Healthcare · Biotechnology

$38.00+1.20%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-47.8M

EPS

$-0.81

EPS estimate

$-0.74

EPS came in at -0.81 against a street estimate of -0.74 — a miss of 9.5%.

Key statistics

Market cap

$2.67B

Forward P/E

0.0

P/B

7.53

Book value

$4.98

EPS (TTM)

$-3.06

52-week high

$43.25

52-week low

$20.65

50-day MA

$34.98

200-day MA

$29.74

Beta

-2.32

Analyst view

Analysts rate Pharvaris BV a buy (8 buy, 0 hold, 1 sell out of 9) with an average price target of $58.93.

Shareholding

Insiders

6.08%

Institutions

93.11%

Largest institutional holders

Fund	Stake
General Atlantic Llc	9.33%
FMR Inc	8.95%
Foresite Capital Management IV, LLC	6.81%
venBio Partners LLC	6.61%
Viking Global Investors LP	5.20%
EQT Fund Management S.à r.l.	4.88%
Deerfield Management Co	4.45%
Bain Capital Life Sciences Investors, LLC	3.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pharvaris BV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.